Further evidence for this PAR2-PDGFR crosstalk comes from the observation that the PAR2-selective agonist peptide, 2-furoyl-LIGRLO-NH2, induces phosphorylation and activation of the PDGFR in liver carcinoma cells [53]. The gene discussed is PDGFRB; the disease is hepatocellular carcinoma.